DDS Founders Fund · Series Seed SPV · June 2026

Intelligent Wound Care
That Acts on the Wound

Patent-pending platforms that sense the wound environment and deliver therapy autonomously — no electronics, no external intervention required.

Series Seed SAFE

$22M Post-Money Cap

10% Discount

Physician-Founded

Dual Patent-Pending

$25B+

Global TAM

$22.5B

US Medicare Chronic Wound Cost

$5M

Target Raise

$22M

Post-Money Cap

The Opportunity

Wound care has stayed
passive for decades

HealCue develops two patent-pending platforms — Smart Sutures and Smart Patches — that respond to the wound and deliver therapy on their own. No power, no electronics, no clinician intervention required at the point of care.

Founded and entirely bootstrapped by Dr. Mohammed N. Quadri, MD, MBA — a practicing physician and named inventor on both patents — this SPV is the company's first external capital. The founder has taken no salary and personally funded formation, IP, and active laboratory work.

The market opportunity spans $25B+ across surgical sutures, advanced wound care, and defense. Comparable exits — Acera Surgical (acquired by Solventum for up to $850M in 2025) and Embody (acquired by Zimmer Biomet for up to $275M in 2023) — validate both the technology category and the acquirer universe.

Power-Free Autonomy

Chemistry-encoded response with no electronics. Triggered by the wound itself — rugged by design and hard to replicate.

Dual IP Portfolio

Two USPTO provisional filings with full utility applications in preparation for 2026. All IP retained in the U.S.

Platform, Not a Product

One responsive-material approach spanning sutures and patches across civilian clinical, defense, and specialty markets.

Founder-Bootstrapped to Date

Every dollar of formation, IP, and lab work has been personally funded. No salary taken. This SPV opens the work to aligned partners for the first time.

The Platforms

Two platforms,
one responsive-material approach

Power-Free

Smart Sutures™

A biodegradable composite suture engineered for pH-responsive drug delivery at the wound site. No electronics, no power source — built for any setting from the OR to the field.

Silk fibroin composite with pH-triggered release
Fully power-free, no electronics on the suture
Phase 1 bench work underway; silk fibroin extraction in progress

Chemistry-First + Optional Sensing

Smart Patches™

A multilayer nanofibrous scaffold with autonomous antimicrobial release matched to wound type. Chemistry-first with passive failsafe, plus an optional connected sensing layer.

Antimicrobial release matched by wound type
Material optimization and SEM morphology complete; FTIR active
Optional connected sensing layer for clinical monitoring

How It Works

Sense

The material responds to pH shifts and biochemical signals in the wound environment.

Release

Therapy is delivered precisely where and when needed — no power, no external input.

Heal

Reduces infection risk and supports healing across the full course of recovery.

High-level mechanism only. Proprietary formulations and fabrication detail are held internally.

The Raise

Series Seed SPV
via DDS Founders Fund

SPV Terms — Series Seed SAFE

Instrument

SAFE

Target Raise

$5,000,000

Valuation Cap

$22M Post-Money

Discount

10%

Minimum Check

$250,000

Pro-Rata Rights

$500K and above

Option Pool

15% Post-Money

Rolling

Vehicle

Sydecar / DDS Founders Fund

Legal

Morrison & Foerster LLP

Initial tranche of $60,000 for prototype development, due June 12, 2026. Subsequent tranche is the balance of the $250,000 minimum. Total SPV commitment remains open based on the final raise.

Use of Proceeds

Prototype development — sutures and patches

Materials and characterization

Laboratory operations

IP and utility patent filings

Regulatory pre-submission preparation

Development Milestones

Now

Active bench workPhase 1 suture lab underway; silk fibroin extraction in progress. Smart Patches SEM complete, FTIR active.

Q3 '26

Coated prototype + in-vitro testingComposite fiber fabrication, SEM/FTIR characterization, continued patch work.

Q4 '26

Sterilized prototype + in-vivo dataPilot rat study — first biological efficacy signal.

2027

Pre-clinical package + FDA pre-submissionSeries A fundraising supported by full data package.

Non-Dilutive Pathway — DARPA BTO

Abstract prepared for BAA HR001126S0003. Targeting ~$2M OT for Prototype over 18 months toward an FDA pre-submission package. Federal distribution relationship with a veteran-led SDVOSB distributor also in formation. No award made; no agreement executed.

Leadership

Led by clinicians
and scientists

Founder & CEO

Dr. Mohammed N. Quadri, MD, MBA

Practicing physician and operator. Named inventor on both USPTO provisional patents. Self-funded the company from formation through active lab work. No salary taken.

Chief Clinical Officer

Dr. Traci Kimball, MD, MBA, CWSP

Board-certified wound specialist and general surgeon. Twelve years in wound care including service as a wound-management medical director. Founder of The WISH Clinic.

CSO

Chief Scientific Officer

Name Available Under NDA

Materials scientist, PhD and FRSC. 36 granted patents. Leads laboratory execution across both platforms. Identity available to qualified investors under NDA.

Acquired by Solventum · December 2025

Acera Surgical

Up to $850M

Electrospinning wound platform — a direct technology comparable to HealCue's nanofibrous scaffold.

Acquired by Zimmer Biomet · 2023

Embody

Up to $275M

DARPA and DoD-funded — a precedent for HealCue's non-dilutive government pathway and acquirer appetite.

Sources: company and acquirer announcements, 2023 and 2025.

Documents